EP1214079A1 - Medicament pour traiter des fractures - Google Patents

Medicament pour traiter des fractures

Info

Publication number
EP1214079A1
EP1214079A1 EP00952791A EP00952791A EP1214079A1 EP 1214079 A1 EP1214079 A1 EP 1214079A1 EP 00952791 A EP00952791 A EP 00952791A EP 00952791 A EP00952791 A EP 00952791A EP 1214079 A1 EP1214079 A1 EP 1214079A1
Authority
EP
European Patent Office
Prior art keywords
bone
drug
group
bisphosphonate
pamidronate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00952791A
Other languages
German (de)
English (en)
Other versions
EP1214079A4 (fr
Inventor
David G Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Alexandra Hospital for Children
Original Assignee
Royal Alexandra Hospital for Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Alexandra Hospital for Children filed Critical Royal Alexandra Hospital for Children
Publication of EP1214079A1 publication Critical patent/EP1214079A1/fr
Publication of EP1214079A4 publication Critical patent/EP1214079A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Definitions

  • the present invention consists in a drug selected from a group consisting of at least one bisphosphonate when used for treating a fracture.
  • the drug of either the first or the second aspect is the bisphosphonate Zoledronate.
  • At least one bisphosphonate should be administered to the patient early in the course of treatment.
  • different bones and different types of fracture heal at varying rates. Accordingly, the early phase of the course depends upon such variables.
  • zoledronate or pamidronate and/or another drug from the class of bisphosphonates is used for the manufacture of a medicament for promoting bone growth or treating a fractured bone.
  • Suitable stimulators 12 include a rotating eccentric mass. an electromagnetic shaker, and a variable frequency pulsed ultrasonic transducer.
  • the stimulator 12 can incorporate a stimulus sensor, such as a force transducer, to monitor the stimulus provided to the bone by the stimulator 12.
  • the stimulation imparted by device 10 is regulated to be at the same, or approximately the same, frequency as the resonant frequency of the bone, the promotion of bone tissue growth is optimised and occurs at a faster rate than if the bone is simply stimulated at a frequency unrelated to the resonant frequency of the bone.
  • the device 10 could be applied transcutaneously to a bone with a fixation means such as an intramedullary nail holding the bone pieces together.
  • a fixation means such as an intramedullary nail holding the bone pieces together.
  • the formation of bone between the pieces of bone may be increased by the stimulation of the bone and the fixation means at. or approximate, the bone's resonant frequency.
  • Each of the following examples relates to the administration of a bisphosphonate in distraction osteogenesis.
  • One of the aims of distraction osteogenesis is to lengthen the limb upon which the procedure is performed. The performance of a distraction osteogenesis necessitates fracturing of the bone. Following placement of an external frame on the limb, the bone is cut. During healing, the new bone forms as the frame is slowly distracted.
  • mice were randomised such that eight animals were operated on and given saline-only infusions (controls), eight animals were given 0.1 mg/kg zoledronate over 20 minutes at the time of surgery (single dose zoledronate). and a further eight animals were given a second dose of zoledronate 0.1 mg/kg on day 14 (re-dosed zoledronate).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un médicament choisi dans un groupe constitué de bisphosphonates, qui est destiné à favoriser la croissance osseuse et à traiter des fractures.
EP00952791A 1999-08-19 2000-08-17 Medicament pour traiter des fractures Withdrawn EP1214079A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ232599 1999-08-19
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (fr) 1999-08-19 2000-08-17 Medicament pour traiter des fractures

Publications (2)

Publication Number Publication Date
EP1214079A1 true EP1214079A1 (fr) 2002-06-19
EP1214079A4 EP1214079A4 (fr) 2004-03-24

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00952791A Withdrawn EP1214079A4 (fr) 1999-08-19 2000-08-17 Medicament pour traiter des fractures

Country Status (16)

Country Link
EP (1) EP1214079A4 (fr)
JP (1) JP2003507426A (fr)
KR (1) KR20020027562A (fr)
CN (1) CN100345548C (fr)
AU (1) AUPQ232599A0 (fr)
BR (1) BR0013416A (fr)
CA (1) CA2381302A1 (fr)
HK (1) HK1048441B (fr)
HU (1) HUP0202396A3 (fr)
IL (1) IL148166A0 (fr)
NO (1) NO20020784D0 (fr)
NZ (1) NZ517538A (fr)
PL (1) PL353485A1 (fr)
SK (1) SK2382002A3 (fr)
WO (1) WO2001013922A1 (fr)
ZA (1) ZA200202160B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425549B2 (en) * 2001-02-06 2008-09-16 The Royal Alexandra Hospital For Children Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
WO2002080933A1 (fr) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children Medicament a utiliser en matiere de greffe osseuse
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
EP1508343B1 (fr) * 2003-08-21 2015-11-04 AddBIO AB Implant revêtu de bisphosphonate et son procédé de fabrication
WO2005027921A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
US8940320B2 (en) 2005-10-27 2015-01-27 Thommen Medical Ag Dental implant and production method for said implant
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530360A (en) * 1981-11-19 1985-07-23 Duarte Luiz R Method for healing bone fractures with ultrasound
EP0600834A1 (fr) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Utilisation de dérivés de l'acide méthanediphosphonique pour la fabrication d'un médicament pour le traitement de fractures
WO1994014455A1 (fr) * 1992-12-23 1994-07-07 Merck & Co., Inc. Therapie utilisant des bisphosphonates et des ×strogenes en vue de traiter et de prevenir la resorption osseuse
WO1995030421A1 (fr) * 1994-05-04 1995-11-16 Ciba-Geigy Ag Utilisation de certains derives de l'acide methanebisphosphonique dans la prevention du relachement et de la migration de prothese

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011786A1 (fr) * 1991-12-17 1993-06-24 Procter & Gamble Pharmaceuticals, Inc. Methodes de traitement de l'osteoporose faisant appel a des bisphosphonates et a une hormone parathyroidienne
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
AU703887B2 (en) * 1995-06-06 1999-04-01 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530360A (en) * 1981-11-19 1985-07-23 Duarte Luiz R Method for healing bone fractures with ultrasound
EP0600834A1 (fr) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Utilisation de dérivés de l'acide méthanediphosphonique pour la fabrication d'un médicament pour le traitement de fractures
WO1994014455A1 (fr) * 1992-12-23 1994-07-07 Merck & Co., Inc. Therapie utilisant des bisphosphonates et des ×strogenes en vue de traiter et de prevenir la resorption osseuse
WO1995030421A1 (fr) * 1994-05-04 1995-11-16 Ciba-Geigy Ag Utilisation de certains derives de l'acide methanebisphosphonique dans la prevention du relachement et de la migration de prothese

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENISSEN H ET AL: "CERAMIC HYDROXYAPATITE IMPLANTS FOR THE RELEASE OF BIPHOSPHONATE" BONE AND MINERAL, SHANNON, IE, vol. 25, no. 2, 1994, pages 123-134, XP001015353 *
ECK J. ET AL: 'Diagnosis and Treatment of Common Metabolic Spinal Disorders in the Geriatric Population' SOUTHERN MEDICAL JOURNAL vol. 91, no. 12, 1998, pages 1089 - 1097 *
SABOKBAR A. ET AL: 'Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption' ANNALS OF RHEUMATIC DISEASES vol. 57, no. 10, 1998, pages 614 - 618 *
See also references of WO0113922A1 *

Also Published As

Publication number Publication date
HUP0202396A2 (hu) 2002-11-28
HK1048441A1 (en) 2003-04-04
CN1370071A (zh) 2002-09-18
HUP0202396A3 (en) 2005-02-28
NO20020784L (no) 2002-02-18
CA2381302A1 (fr) 2001-03-01
ZA200202160B (en) 2003-08-27
EP1214079A4 (fr) 2004-03-24
NZ517538A (en) 2003-07-25
BR0013416A (pt) 2002-04-30
WO2001013922A1 (fr) 2001-03-01
IL148166A0 (en) 2002-09-12
PL353485A1 (en) 2003-11-17
CN100345548C (zh) 2007-10-31
JP2003507426A (ja) 2003-02-25
KR20020027562A (ko) 2002-04-13
AUPQ232599A0 (en) 1999-09-09
SK2382002A3 (en) 2002-09-10
HK1048441B (zh) 2008-02-22
NO20020784D0 (no) 2002-02-18

Similar Documents

Publication Publication Date Title
WO2002098307A1 (fr) Dispositif permettant l'apport d'un medicament a un os fracture
Little et al. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis: A study in immature rabbits
Pampu et al. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis
Küçük et al. Comparison of local and systemic alendronate on distraction osteogenesis
WO2001013922A1 (fr) Medicament pour traiter des fractures
US20150374747A1 (en) Amorphous calcium carbonate for accelerated bone growth
Oteo-Álvaro et al. Teriparatide (rh [1–34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening
Linderbäck et al. Weak effect of strontium on early implant fixation in rat tibia
Tarvainen et al. Effect of clodronate on fracture healing in denervated rats
Harding et al. A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients
AU781068B2 (en) Drug for treating fractures
AU756540B2 (en) Use of ibandronate for promoting osseointegration of endoprostheses
Alshahrani et al. Ranitidine impairs bone healing and implant osseointegration in rats' tibiae
Kakar et al. Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals
JP2010526064A (ja) 骨組織の成長の育成および保存のための方法および組成物
Saghieh et al. The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study
RU187285U1 (ru) Металлоконструкция для интрамедуллярного остеосинтеза трубчатых костей
Heidari et al. Effect of risedronate on bone resorption during the consolidation phase of distraction osteogenesis: a rabbit model
Savintsev et al. Application of nanostructured carbon implants in surgical treatment of transverse flat feet
Green et al. Postoperative Care, Day by Day
Min et al. Nonsurgical treatment strategies after osteoporotic hip fractures
So et al. A 3D-printed solution for revision lapidus bunionectomy
Diamond et al. Complications of medical treatment: Atypical fractures
A Osman et al. The effect of simvastatin drug on osteogenesis around titanium implant (radiographic and histomorphometric analysis)
EP4274556A1 (fr) Traitement de longues fractures osseuses à l'aide d'abaloparatide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20020313

A4 Supplementary search report drawn up and despatched

Effective date: 20040205

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 19/00 B

Ipc: 7A 61K 31/663 A

Ipc: 7A 61K 31/675 B

17Q First examination report despatched

Effective date: 20041008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080903